Anti-estrogens induce apoptosis of multiple myeloma cells

Blood

Volumn 92, Issue 5, 1998, Pages 1749-1757

  Treon, Steven P ^b   Teoh, Gerrard ^b   Urashima, Mitsuyoshi ^b   Ogata, Atsushi ^b   Chauhan, Dharminder ^b   Webb, Lain J ^b   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; TAMOXIFEN; TOREMIFENE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; FLUORESCENCE ACTIVATED CELL SORTER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0032170090     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.5.1749.417k38_1749_1757     Document Type: Article

References (52)

1. Danel L, Menouni M, Cohen JH, Magaud JP, Lenoir G, Revillard JP, Saez S: Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines. Leuk Res 9:1373, 1985
2. Danel L, Vincent C, Rousset F, Klein B, Bataille R, Flacher M, Durie BG, Revillard JP: Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. J Steroid Biochem 30:363, 1988
3. Medina KL, Kincade PW: Pregnancy related steroids are potential negative regulators of B lymphopoiesis. Proc Nail Acad Sci USA 91:5382, 1994
4. Smithson G, Medina K, Ponting I, Kincade PW: Estrogen suppresses stromal cell dependent lymphopoiesis in culture. J Immunol 155:3409, 1995
5. Baral E, Kwok S, Bercz'i I: Suppression of lymphocyte mitogenesis by tamoxifen. Immunopharmacology 18:57, 1989
6. Narasimhan P: Tamoxifen in the treatment of refractory lymphoma. N Engl J Med 311:1258, 1984
7. Morgan D: Estrogen receptors and lymphocytic lymphoma. Ann Intern Med 95:783, 1981
8. Pottratz ST, Bellido T, Mocharla H, Crabb D, Manolagas S: 17 β estradiol inhibits expression of human interleukin 6 promoter-reporter constructs by a receptor dependent mechanism. J Clin Invest 93:944, 1994
9. Jarvinen LS, Pyrhonen S, Kairemo KJA, Paavonen T: The effect of anti-oestrogens on cytokine production in vitro. Scand J Immunol 44:15, 1996
10. Bataille R, Jourdan M, Zhang XG, Klein B: Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008, 1989
11. Solary E, Guiguet M, Zeller V, Casasnovas RO, Caillot D, Chavanet P, Guy H, Mack G: Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass in multiple myeloma. Am J Hematol 39:163, 1992
12. Kawano M, Hirano T, Matsuda T, Taga T: Autocrine generation and essential requirements of BSF-2/IL-6 for human multiple myeloma. Nature 332:83, 1988
13. Anderson KC, Jones RM, Morimoto C, Leavitt P, Beirut BA: Response patterns of purified myeloma cells to hematopoetic growth factors. Blood 73:1915, 1989
14. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin-6 prevents Dexamethasone-induced myeloma cell death. Blood 84:3063, 1994
15. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J: Ihterleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248, 1995
16. Parker MG: Action of "pure" anti-estrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 26:131, 1993
17. Katzenellenbogen BS, Montano MM, LeGoff P, Schodin DJ, Kraus WL, Bhardwaj B, Fujimoto N: Antiestrogens: Mechanisms and actions in target ceils. J Steroid Biochem Mol Biol 53:1, 1995
18. Dowsett M, Ellis PA, Saccani-Jotti G, Johnston SR, Salter J, Anderson E, Nicholson R, Howell A: Tamoxifen and the pure antiestrogen ICI 182780 induce apoptosis in estrogen receptor positive primary breast cancer in vivo. Proc Annu Meet Am Soc Cancer Res 37:A1268, 1996 (abstr)
19. Chen H, Tritton TR, Kenny N, Absher M, Chiu JF: Tamoxifen induces TGF-beta 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 61:9, 1996
20. Benson JR, Baum M: Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells. Br J Cancer 74:993, 1996
21. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH, Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 3455:43, 1994
22. Lim JS, Ly A, Bhimani R, Frenkel K, Troll W: The chemopreventative agent tamoxifen causes apoptosis. Proc Am Assoc Cancer Res 35:A3693, 1994 (abstr)
23. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL: High dose tamoxifen, a potential multidrug resistance reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 84:1811, 1992
24. Berman E, McBride M, Lin S, Menedez-Botet C, Tong W: Phase I trial of high dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 9:1631, 1995
25. Couldwell WT, Hinton DR, Surnock AA, DeGiorgio CM, Weiner LP, Apuzzo MLJ, Masri L, Law RE, Weiss MH: Treatment of recurrent malignant gliomas with chronic oral high dose tamoxifen. Clin Cancer Res 2:619, 1996
26. Hitzler JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA: Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 78:1996, 1991
27. Okuno Y, Takahashi T, Suzuki A, Fukumoto M, Nakamura K, Fukui H, Koishihara Y, Ohsugi Y, Imura H: Acquisition of growth autonomy and tumorigenicity by an interleukin-6 dependent human myeloma cell line transfected with interleukin-6 cDNA. Exp Hematol 20:395, 1992
28. Berthois Y, Katzenellenbogen JA, Katzellenbogen BS: Phenol red in tissue culture media is a weak estrogen: Implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 83:2496, 1986
29. Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867, 1991
30. Kangas L: Introduction to toremifene. Breast Cancer Res Treat 16(S):S3, 1990
31. 3J. Hanstein B, Liu H, Yancisin MC, Brown M: Functional analysis of a novel estrogen receptor beta isoform. Mol Endocrinol (in press)
32. Barut BA, Zon LI, Cochran MK, Paul SR, Chauhan D, Mohr-bacher A, Fingeroth J, Anderson KC: Role of interleukin 6 in the growth of myeloma derived cell lines. Leuk Res 16:951, 1992
33. Nicoletti I, Migliorati G, Pagliacci MC, Grignatii F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271, 1991
34. Hardin J, MacLeod S, Grigorieva I, Chang R, Bariogie B, Xiao H, Epstein J: Interleukin-6 prevents dexamethasone induced myeloma cell death. Blood 84:3063, 1994
35. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Andferson KG: CD40 ligand triggered interleukin 6 secretion in multiple myeloma. Blood 85:1903, 1995
36. Carbonari M, Cibati M, Fiorilli M: Measurement of apoptotic cells in peripheral blood. Cytometry 22:161, 1995
37. Webb IJ, EickhoffCE, Elias AD, Ayash LJ, Wheeler C, Schwartz G, Demetri G, Anderson KC: Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony stimulating factor (G-CSF): Implications for timing and yield of hematopoietic progenitor cell collections. Transfusion 36:160, 1996
38. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J: Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248, 1995
39. Wang TT, Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55:2487, 1995
40. Pratt C, Texeira C: Regulation of the Bcl-2 proto-oncogene by estrogen in human breast cancer cells. Breast Cancer Res Treat 32(S):31, 1994
41. Burow ME, Beckman BS: Effects of environmental estrogens on apoptotic pathways in breast cancer cells. Proc Am Assoc Cancer Res 37-A1546, 1996 (abstr)
42. Cameron DA, Keen JC, Anderson TJ, Hawkins A, Miller E, Hanby A, Miller WR, Dixon JM: Breast cancer response to tamoxifen is associated with an increase in apoptosis and a fall in bcl-2 expression. Proc Am Assoc Cancer Res 37:A1690, 1996 (abstr)
43. Kandouz M, Siromachkova M, Jacob D, Marquet BC, Therwath A, Compel A: Antagonism between estradiol and progestin on bcl-2 expression in breast cancer cells. Int J Cancer 68:120, 1996
44. Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS: High affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature 288:273, 1988
45. Parisot JP, Hu XF, Sutherland RL, Wakeling A, Zalcberg JR, DeLuise M: The pure anti-estrogen ICI 182,780 binds to a high affinity site distinct from the estrogen receptor. Int J Cancer 62:480, 1995
46. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW, Anderson KC: Interleukin 6 inhibits Fasinduced apoptosis and SAP kinase activation in multiple myeloma cells. Blood 89:227, 1997
47. Chauhan D, Pandey P, Ogata A, Teoh G, Treon S, Urashima M, Kharbanda S, Anderson KC: Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 15:837, 1997
48. Chauhan D, Pandey P, Ogata A, Teoh G, Krett N, Halgren R, Rosen S, Kufe D, Kharbanda S, Anderson KC: Cytochrome-C dependent and independent induction of apoptosis in multiple myeloma cells. J Biol Chem 272:29995, 1997
49. Hemminki K, Widlak P, Hou SM: DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 16:1661, 1995
50. Tannebaum SR: Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Semin Oncol 24:8181, 1997
51. DeFriend DJ, Blarney RE, Robertson JF, Walton P, Howell A: Response to the pure antiestrogen ICI 182,780 after tamoxifen failure in advanced breast cancer. Breast Cancer Treat Res 27:136, 1993
52. Lippo K, Ellmen J, Vanttinen E, Anttila M: Toremifene concentration and multidrug resistance in lung tumors. Cancer Chem Pharmacol 39:212, 1997